Dr Jan Steffel MD FESC FEHRA FHRS: Professor and Vice Chairman of the Department of Cardiology, Senior Consultant, Division of Electrophysiology & Cardiac Devices, University Hear Center Zurich, Switzerland

Episode 3: Dr. Steffel; a lead author of the EHRA Practical Guide, answers the following question in this video series: What do we know about the performance of the 150mg dose, in particular the REDUAL study for thromboembolic & major bleeding events?

Disclosure Statement: Dr. Steffel has received consultant and / or speaker fees from Abbott, Amgen, Astra-Zeneca, Bayer, Berlin Chemie / Menarini, Biosense Webster, Biotronik, Boehringer-Ingelheim, Boston Scientific, Bristol-Myers Squibb, Daiichi Sankyo, Medscape, Medtronic, Merck/MSD, Novartis, Pfizer, Sanofi-Aventis, WebMD, and Zoll. He reports ownership of CorXL. Dr. Steffel has received grant support through his institution from Abbott, Bayer Healthcare, Biosense Webster, Biotronik, Boston Scientific, Daiichi Sankyo, and Medtronic.